CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 5, 2012
Result type: Reports
Project Number: SR0292-000
Product Line: Reimbursement Review

Generic Name: Pirfenidone

Brand Name: Esbriet

Manufacturer: InterMune Canada Inc.

Therapeutic Area: Idiopathic pulmonary fibrosis

Indications: Pulmonary fibrosis (idiopathic, mild to moderate)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 18, 2013

Recommendation Type: Do not list